Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Inclusion Criteria: Each patient must meet all of the following criteria to be enrolled in the study: * ECOG performance status of \< or equal to 2. * Diagnosis of solid tumor malignancy or lymphoma for which standard treatment is no longer effective. * Have a radiographically or clinically evaluable tumor or lymphoma. * Measurable disease as described in the protocol. * Suitable venous access for the study-required blood sampling. * Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse. * Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse. * Voluntary written consent. * Weigh at least 45 kg. * Recovered from the reversible effects of prior antineoplastic therapy. * Meet clinical laboratory values during the screening period as specified in the protocol. * Left ventricular ejection fraction (LVEF) \> or equal to 50% by echocardiogram or multiple acquisition scan (MUGA). Exclusion Criteria: Patients meeting any of the following exclusion criteria are not to be enrolled in the study: * Diagnosis of primary CNS malignancy or carcinomatous meningitis. * Patient has symptomatic brain metastasis. * Prior bone allogeneic bone marrow or stem cell transplant. * Prior radiotherapy involving \> or equal to 30% of the hematopoietically active bone marrow, within 21 days before the start of the study drug. * Systemic antineoplastic therapy within 28 days before the start of the study drug, except for luteinizing hormone-releasing-hormone (LHRH) agonist therapy. * Exposure to nitrosureas or mitomycin C within 42 days before the start of the study drug. * Treatment with monoclonal antibodies within 28 days before the start of the study drug. * Known allergy or hypersensitivity to compounds of similar chemical composition to TAK-901 or its excipient, Captisol. * Female patients who are lactating or who have a positive serum pregnancy test during the screening period or a positive serum pregnancy test during the screening period. * Myocardial infarction within 6 months before enrollment. * Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Abnormalities on 12-lead electrocardiogram (ECG) as specified in the protocol. * Infection requiring systemic anti-infective therapy within 14 days before the start of study drug. * Known human immunodeficiency virus (HIV)positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection. * Diagnosed or treated for another malignancy within 2 years before the start of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. * Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment. * Treatment with any investigational products within 28 days before the first dose of study drug. * Systemic use of strong CYP3A inhibitors or inducers (as specified in the protocol) within 14 days before the first dose of study drug.